Clinical Indication ID & Name
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Test Group
Specialties
Test code
R454.1
Test name
Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Target genes
Test scope
*2, *3 and *17 alleles
Test method/ technology
Targeted variant testing
Optimal Family Structure
n/a
Eligibility Criteria
Testing Criteria
Testing is available to patients with:
1. symptomatic obstructive hypertrophic cardiomyopathy who have a New York Heart Association class of 2 to 3 AND
2. are eligible for treatment with mavacamten in line with NICE TA 913 (where mavacamten is an add on to individually optimised standard care that includes beta blockers, non-dihydropyridine calcium-channel blockers or disopyramide, unless these are contraindicated).
Where in Pathway
At prescribing decision
Requests for this test will only be accepted from centres that are commissioned to prescribe Mavacamten
Commissioning group
n/a
Overlapping idications
n/a
Address for samples/request forms
Contact with queries
Supporting documents
n/a
Education resources
n/a
Turn around times
n/a
Request form download
Consent record
See consent guidance in test request form
Sample requirements
n/a